Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers

被引:68
作者
Hunt, RH
Armstrong, D
James, C
Chowdhury, SK
Yuan, YH
Fiorentini, P
Taccoen, A
Cohen, P
机构
[1] McMaster Univ, Med Ctr, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada
[2] Negma Lerads, F-78771 Magny Les Hameaux, France
关键词
D O I
10.1111/j.1572-0241.2005.41956.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: To compare the inhibitory effect of a novel proton pump inhibitor (PPI), tenatoprazole 40 mg once daily, with esomeprazole 40 mg once daily on intragastric acidity. METHODS: A randomized, investigator-blind, two-way, crossover study was conducted in 30 healthy Helicobacter pylori negative male volunteers. Tenatoprazole 40 mg or esomeprazole 40 mg was administered once daily for 7 consecutive days with a 4-wk washout period between treatments. Ambulatory 24-h intragastric pH was recorded at baseline, after 7 days' treatment, and 3 and 5 days after treatment was stopped. RESULTS: At presumed steady-state (day 7), median 24-h pH values were 5.02 and 4.79 for tenatoprazole and esomeprazole, respectively. There was a significant difference between tenatoprazole and esomeprazole during the nocturnal period when mean pH was 4.64 +/- 0.67 versus 3.61 +/- 0.90, respectively (p < 0.0001), as well as a significantly higher mean percentage of time with pH >4 on tenatoprazole (72.5 +/- 14.9 vs 62.2 +/- 13.6, p < 0.0001). The effect of tenatoprazole was still present 5 days after treatment withdrawal especially during the night-time. The mean area under the plasma concentration-time curve and elimination half-time was significantly higher in the tenatoprazole group as compared with the esomeprazole group. CONCLUSION: Tenatoprazole 40 mg daily provides a prolonged duration of acid suppression and a shorter nocturnal acid breakthrough in healthy volunteers, even after stopping the drug. Thus, tenatoprazole may provide greater clinical efficacy for patients in whom a once daily PPI is ineffective. Further studies are indicated.
引用
收藏
页码:1949 / 1956
页数:8
相关论文
共 37 条
[1]
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers - Results of a double-blind, randomized, multicenter study [J].
Agrawal, NM ;
Campbell, DR ;
Safdi, MA ;
Lukasik, NL ;
Huang, B ;
Haber, MM .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (10) :1455-1461
[2]
The role of acid suppression in patients with endoscopy-negative reflux disease:: the effect of treatment with esomeprazole or omeprazole [J].
Armstrong, D ;
Talley, NJ ;
Lauritsen, K ;
Moum, B ;
Lind, T ;
Tunturi-Hihnala, H ;
Venables, T ;
Green, J ;
Bigard, MA ;
Mössner, J ;
Junghard, O .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (04) :413-421
[3]
Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects [J].
Armstrong, D ;
Bair, D ;
James, C ;
Tanser, L ;
Escobedo, S ;
Nevin, K .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (07) :705-711
[4]
The Canadian Registry on nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting [J].
Barkun, A ;
Sabbah, S ;
Enns, R ;
Armstrong, D ;
Gregor, J ;
Fedorak, RN ;
Rahme, E ;
Toubouti, Y ;
Martel, M ;
Chiba, N ;
Fallone, CA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (07) :1238-1246
[5]
ROLE OF GASTRIC-ACID SUPPRESSION IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
HUNT, RH .
GUT, 1992, 33 (01) :118-124
[6]
IS THERE AN OPTIMAL DEGREE OF ACID SUPPRESSION FOR HEALING OF DUODENAL-ULCERS - A MODEL OF THE RELATIONSHIP BETWEEN ULCER HEALING AND ACID SUPPRESSION [J].
BURGET, DW ;
CHIVERTON, SG ;
HUNT, RH .
GASTROENTEROLOGY, 1990, 99 (02) :345-351
[7]
Castell DO, 2003, AM J GASTROENTEROL, V98, P213
[8]
EFFECT OF AN ACIDIC ENVIRONMENT ON THE SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO TROSPECTOMYCIN AND OTHER ANTIMICROBIAL AGENTS [J].
DEBETSOSSENKOPP, YJ ;
NAMAVAR, F ;
MACLAREN, DM .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (04) :353-355
[9]
Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteers [J].
Domagala, F ;
Ficheux, H .
GASTROENTEROLOGY, 2003, 124 (04) :A231-A231